Traders should monitor the ASCO presentation on June 1, 2026, for safety and dosimetry signals that could de-risk the broader ProstACT Global trial and boost confidence in TLX591-Tx’s differentiation. Positive data could catalyze re-rating ahead of Part 2 readout.
Price Chart
Executive Summary
Telix Pharmaceuticals announced that safety and dosimetry data from Part 1 of its Phase 3 ProstACT Global trial for TLX591-Tx will be presented as a late-breaking oral presentation at the 2026 ASCO Annual Meeting. The selection for a high-profile session underscores the potential clinical relevance of its radiopharmaceutical therapy in metastatic castration-resistant prostate cancer.
Key Facts
- Safety and dosimetry data from Part 1 of the ProstACT Global Phase 3 trial will be presented at ASCO 2026 as a late-breaking oral presentation.
- Part 1 included 36 patients and assessed tolerability, biodistribution, and radiation dose profile of TLX591-Tx in combination with standard of care.
- TLX591-Tx shows reduced kidney toxicity and minimal salivary/lacrimal gland uptake compared to other PSMA-targeted therapies.
- The abstract was selected for a high-visibility session at ASCO, indicating strong interest from the oncology community.
Financial Impact
Potential long-term commercial upside due to favorable safety profile and high-visibility data readout, though no immediate revenue impact.
Risk Factors
- TLX591-Tx remains investigational and has not received marketing authorization.
- Part 1 data are preliminary and from a small cohort; efficacy results from the larger Part 2 are still pending.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278510 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $12.83 $11.95 | ▼ −6.86% | ▼ −8.99% | $10.55 (−17.77%) |
Sep 14, 2026 18d ago | Press Release | $11.78 $11.31 | ▼ −3.99% | ▼ −4.10% | $10.55 (−10.44%) |
Sep 2, 2026 4w ago | 6-K | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Sep 1, 2026 4w ago | Press Release | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Aug 20, 2026 6w ago | 6-K | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Aug 20, 2026 6w ago | Press Release | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Jul 30, 2026 9w ago | Press Release | $9.89 $11.52 | ▲ +16.48% | ▲ +12.97% | $10.55 (+6.67%) |
Jul 21, 2026 10w ago | Press Release | $10.32 $10.10 | ▼ −2.13% | ▲ +0.27% | $10.55 (+2.23%) |
Jul 21, 2026 10w ago | 6-K | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
Jul 20, 2026 10w ago | Press Release | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access